Apax Partners Acquires French CRO Porsolt
Apax Partners, a London-based private equity firm, announced on February 21 that it acquired a majority stake in Porsolt, a global preclinical contract research organization (CRO) located in Le Genest-Saint-Isle, France. This partnership will enhance Porsolt’s service offering and expand its portfolio and capabilities for drug screening, efficacy and safety for clients worldwide. Terms of the deal were not disclosed. Porsolt works with pharmaceutical and biotechnology companies, academic institutes and not-for-profit organizations, offering specialized preclinical testing services across many disease areas, physiological systems and processes. The funds managed and advised by Apax... Read More »
Charles River Laboratories acquires SAMDI Tech for $50 Million
Charles River Laboratories International, Inc. (NYSE: CRL) announced on January 30 that it acquired SAMDI Tech, Inc. The purchase price was $50 million in cash for 80% ownership. Based in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS for identifying binding interactions. Charles River Laboratories is a provider of research tools and integrated support services that enable drug discovery and development, including genetically and virally defined purpose-bred lab animals. In 2021, the company reported revenue of $3.54 billion. The combination of Charles River’s... Read More »
Huma Acquires German CRO Alcedis
Huma Therapeutics Limited, a global digital health company, announced on January 9 its acquisition of Alcedis GmbH for an undisclosed price. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials. Alcedis GmbH is a contract research organization (CRO) for data driven clinical research and technology utilization. Headquartered in Hessen, Germany, Alcedis has more than 25 years of clinical trial experience. Huma Therapeutics produces applications that integrate health data from hospital databases as well as patient wearables and... Read More »
Hillhouse Acquires CRO George Clinical
George Clinical announced on December 9 that it has entered into a sale agreement with Hillhouse, a Beijing-based global investment firm with deep experience in partnering with and supporting healthcare businesses. The George Institute will hold a minority stake in George Clinical following the acquisition and will maintain a collaboration in applicable scientific areas such as in the Global Kidney Patients Trials Network. BofA Securities acted as lead financial advisor on the transaction and Lazard Australia acted as co-advisor. Herbert Smith Freehills LLP acted as legal advisor on the transaction. Financial terms of the transaction were not disclosed. George Clinical is a global clinical... Read More »
Arlington Capital Partners’s Everest Clinical Research Acquires Brightech International
Everest Clinical Research, an Arlington Capital Partners portfolio company, announced on December 1 its acquisition of Brightech International. Brightech will continue to be led by Dr. Tai Xie, the company’s CEO and founder, and the existing management team. Terms of the deal were not disclosed. Founded in 2002, Brightech International is a contract research organization (CRO) that specializes in complex, value-add biostatistics, programming and clinical data management services. Like Everest, Brightech has built a reputation as a critical partner for some of the world’s largest pharmaceutical and biotech companies. In addition to its New Jersey headquarters, Brightech has an expanded... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
